Information Provided By:
Fly News Breaks for March 4, 2020
Mar 4, 2020 | 16:50 EDT
Citi analyst Joanne Wuensch initiated coverage of Tandem Diabetes with a Neutral rating and $89 price target. The analyst notes that the company has evolved to become more than just a traditional insulin pump company thanks to its customer focus and product innovation. Wuensch further cites the touchscreen interface and rechargeable batter of its new t:slim X2 pump while adding that its next-gen Control-IQ system is also gaining momentum. The analyst sees 2020 for Tandem Diabetes as an investment year however and will await a better entry point to get more constructive on the stock.